Anthony E. Maida III - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 3, 2026
Anthony E. Maida III has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Profile
Anthony E. Maida III is DIRECTOR AND CMO - TRANS. MED. at Oncotelic Therapeutics, Inc. (OTLC). Maida has reported 1 insider filing with the SEC since 2026. The most recent filing was in July 2026.
| Role | DIRECTOR AND CMO - TRANS. MED., Director |
|---|---|
| Notability | 26/100 |
Board memberships
- Oncotelic Therapeutics, Inc.
Reported roles
- DIRECTOR AND CMO - TRANS. MED.
Awards & honors
- Listed as Director and Chief Medical Officer for Translational Medicine at Oncotelic Therapeutics, Inc. in the 2026 SEC filing
Trading Pattern
InsiderAlpha's records for Anthony E. Maida III go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Anthony E. Maida III has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- DIRECTOR AND CMO - TRANS. MED., Director at Oncotelic Therapeutics, Inc. (OTLC) - 1 filing, 2026
Companies - Last 90 Days
- Oncotelic Therapeutics, Inc. (OTLC) - 1 filing, last 2026-07-14
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Anthony E. Maida III has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Vuong Trieu - $37K of OTLC open-market activity in the last 12 months
- Amit B. Shah - $1K of OTLC open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Apollo Principal Holdings B GP, LLC
- Apollo Principal Holdings B, L.P.
- ARCH Venture Partners XII, LLC
- ARCH Venture Partners XIII, LLC
- Audax Private Credit Business, LP
- Milton C. Ault III
- BAIN CAPITAL INVESTORS LLC
- Bain Capital Life Sciences Investors, LLC
Frequently Asked Questions
Who is Anthony E. Maida III?
Anthony E. Maida III is DIRECTOR AND CMO - TRANS. MED. at Oncotelic Therapeutics, Inc. (OTLC). Maida has reported 1 insider filing with the SEC since 2026. The most recent filing was in July 2026.…
How many SEC Form 4 filings has Anthony E. Maida III submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Anthony E. Maida III's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Anthony E. Maida III profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.